D. Irwin

J. Glaspy, L. Damon, D. Irwin, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

S. Jagannath, J. Lutzky, B. Durie, 2006 .

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

D. Esseltine, P. Sonneveld, P. Richardson, 2008, British journal of haematology.

Hematologic Profiles in the Phase 3 APEX Trial.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2005 .

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2004, British journal of haematology.

Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2007, British journal of haematology.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.

H. Keer, T. Reid, R. Natale, 2004, Lung cancer.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

A. Jakubowiak, A. Krishnan, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

S. Jagannath, D. Vesole, B. Durie, 2010, British journal of haematology.

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

S. Jagannath, D. Schenkein, J. Lutzky, 2005, British journal of haematology.

Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

P. Sonneveld, J. Massaro, P. Richardson, 2008, British journal of haematology.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma

P. Sonneveld, K. Anderson, S. Lonial, 2005 .

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

A. Jakubowiak, A. Krishnan, S. Lonial, 2008 .

Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience

K. Ahrar, S. Matin, J. Karam, 2023, Cancers.

Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study.

P. Sonneveld, P. Richardson, W. Dalton, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

S. Jagannath, D. Schenkein, J. Lutzky, 2005 .

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

H. Goldschmidt, P. Sonneveld, K. Anderson, 2005 .

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Shaji K. Kumar, D. Reece, J. Zeldis, 2006 .

A Phase 2 Study of Bortezomib as First Line Therapy In Patients with Multiple Myeloma

S. Jagannath, D. Schenkein, J. Lutzky, 2004 .

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2004 .

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

R. Neuwirth, P. Sonneveld, P. Richardson, 2009, British journal of haematology.

Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)

M. Carducci, D. Petrylak, M. Doukas, 2004 .